<?xml version="1.0" encoding="UTF-8"?>
<ref id="B116-biomedicines-08-00060">
 <label>116.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Andtbacka</surname>
    <given-names>R.H.</given-names>
   </name>
   <name>
    <surname>Curti</surname>
    <given-names>B.D.</given-names>
   </name>
   <name>
    <surname>Hallmeyer</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Feng</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Paustian</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Bifulco</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Fox</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Grose</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Shafren</surname>
    <given-names>D.</given-names>
   </name>
  </person-group>
  <article-title>Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment</article-title>
  <source>J. Immunother. Cancer</source>
  <year>2015</year>
  <volume>3</volume>
  <fpage>P343</fpage>
  <pub-id pub-id-type="doi">10.1186/2051-1426-3-S2-P343</pub-id>
 </element-citation>
</ref>
